Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 as Adjunctive Treatment for Major Depressive Disorder
NCT04688164Phase 3Completed
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esmethadone in major depressive disorder (MDD), sponsored by Relmada Therapeutics, Inc.. Started Jan 2021; status: completed.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04688164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688164.